GSK and Theravance announce combination ICS/LABA Phase II results in the … – MarketWatch (press release)

GSK and Theravance announce combination ICS/LABA Phase II results in the
MarketWatch (press release)
Our ongoing collaboration with GSK includes the Phase III programmes in both COPD and asthma, which are already underway for Relovair and its components.
Theravance Announces Results From Phase II Study For Developmental Combination Stock Markets Review

all 10 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *